▎ 摘　　要

NOVELTY - Acid-responsive Fe3O4-RGO-MTX nanomedicine comprises Fe3O4-RGO (iron oxide-reduced graphene oxide) carrier, and MTX (methotrexate) supported on the surface of Fe3O4 nanoparticles and on RGO sheet. USE - Acid-responsive Fe3O4-RGO-MTX nanomedicine for treating tumor (claimed). ADVANTAGE - The acid-responsive Fe3O4-RGO-MTX nanomedicine acts as a carrier of MTX, and has magnetic targeting effect while improving the biological affinity of the carrier, and RGO's unique monoatomic thickness and two-dimensional planar structure can greatly improve the drug loading and sustained release effect of the anticancer drug MTX, and improve the drug efficacy and bioavailability. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for preparing the acid-responsive Fe3O4-RGO-MTX nanomedicine, which involves: (A) dissolving ferric chloride hexahydrate, RGO and sodium acetate in ethylene glycol, uniformly dispersing by ultrasonic agitation, then adding polyethylenimine and ultrasonically stirring to obtain a uniformly dispersed reaction liquid, hydrothermally reacting, and purifying and washing the obtained product, and vacuum drying to obtain Fe3O4-RGO nanoparticles, uniformly dispersing in water with methotrexate; and (B) carrying out the light-proof reaction until the reaction completed, and subjecting the obtained product to purification washing and freeze-drying to obtain the nanomedicine.